Earnings ·
Precipio reports Q3 revenue of $7.3M, up 8% year-over-year
PRPOPrecipio, Inc.
Precipio announced third-quarter financial results for the period ending September 30, 2026, reporting record quarterly revenue of $7.3 million, an 8% increase from $6.8 million in Q3-2025 and a modest rise from $7.0 million in Q2-2026. Revenue comprised $1.0 million in product sales, up 40% year-over-year, and $6.3 million in pathology revenue, up 5%. The company reported Adjusted EBITDA of $0.4 million compared to $0.5 million in the prior year period and generated $0.6 million in cash flow from operations. Total cash increased by $0.5 million to exceed $3.5 million at quarter-end. Precipio is a healthcare biotechnology company focused on developing cancer diagnostics products and services.